Elon Musk Asks for Reason US Can’t Afford Healthcare — Mark Cuban Gives 7 (and a Solution)

Elon Musk isn’t known for mincing words, and when he recently took to X (formerly Twitter) to ask why the U.S. can’t afford healthcare, he got an answer he may not have expected. Billionaire entrepreneur Mark Cuban didn’t just respond — he laid out a scathing critique of the system and pinpointed seven major reasons why healthcare costs are out of control.

Learn More: Here’s What Could Happen to Your Money in Trump’s First 40 Days in Office

Read Next: 6 Subtly Genius Moves All Wealthy People Make With Their Money

Musk’s original question, “Shouldn’t the American people be getting their money’s worth?” cuts to the heart of the issue. It reflects a growing sentiment that Americans are paying exorbitant healthcare costs but not receiving adequate value.

But Cuban — ever the problem-solver — didn’t stop there. He’s also presented a bold solution that could upend the pharmaceutical industry and force real change. The billionaire broke down where the system is failing and how he plans to fix it.

Mark Cuban’s Seven-Point Reality Check for CEOs

Instead of pointing fingers at the government or the system at large, Cuban argued that self-insured companies are part of the problem because of the contracts they sign with insurers and pharmacy benefit managers (PBMs). These deals, he claims, lock businesses into an overpriced system that benefits everyone — except the patients and the companies footing the bill.

Here’s the reality check Cuban dropped on business leaders:

Consider This: If Trump Eliminates the Department of Education, Do You Still Have To Pay Your Student Loans?

1. You Don’t Even Own Your Own Data

When businesses sign with big PBMs, they give up access to their own claims data, meaning they can’t even see where their money is really going. No data means no power to negotiate better deals.

2. The Drugs Your Employees Get? Not Your Choice

PBMs — not the companies paying the bill — decide which drugs employees can access. This often means prioritizing expensive medications over more effective, cheaper alternatives.

3. ‘Specialty Drugs’ Are a Pricing Scam

Cuban called out one of the biggest rip-offs in healthcare — so-called “specialty drugs” that aren’t actually special. PBMs mark up the price, forcing employers to pay more, even when identical alternatives exist at a fraction of the cost.

4. Your Sickest Employees Are Subsidizing the System

PBMs structure rebates so that the sickest and oldest employees end up shouldering the highest costs, leading to higher deductibles, bigger co-pays and worse health outcomes.

5. Independent Pharmacies Get Crushed — And That Hurts Everyone

PBM contracts reimburse independent pharmacies at rates lower than their actual costs, forcing them out of business. Fewer pharmacies mean less competition — which means higher prices and less access for consumers.

6. CEOs Are Handcuffed from Negotiating Better Deals

PBM contracts ban direct negotiations with drug manufacturers, blocking companies from securing better pricing for employees.

7. You Signed a Contract That Silences You

These contracts come with NDAs, meaning even if a CEO wants to talk about the company’s PBM deal, they legally couldn’t. This secrecy keeps CEOs in the dark and prevents businesses from exposing the system.

Cuban’s Fix: A Direct-to-Consumer Pharmaceutical Model

Cuban isn’t just talking — he’s actively working to disrupt the system. His company, Cost Plus Drugs, eliminates PBMs entirely, selling medications directly to consumers with full transparency — no hidden fees and no artificial markups. Musk’s question may have been simple, but Cuban’s answer could be a wake-up call. If his model takes off, it could be the disruption the industry desperately needs.

More From GOBankingRates

This article originally appeared on GOBankingRates.com: Elon Musk Asks for Reason US Can’t Afford Healthcare — Mark Cuban Gives 7 (and a Solution)

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Info icon

This data feed is not available at this time.

Data is currently not available

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.